Join a Trial
As one of its primary objectives, our dynamic research program is working to identify which patients stand to benefit the most from proton therapy. Many of our radiation oncologists are leading large national clinical trials that are available to our patients. Ninety-seven percent (97%) of our patients are enrolled in one of these studies or in one of the many other clinical trials available at our center.
Patients interested in participating in any of these clinical trials should speak to their radiation oncologist about eligibility.
Current Clinical Trials
Learn about the various clinical trials that are currently enrolling New York Proton Center patients.
Breast Cancer
PCG BRE 007-12 Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer: NCT01766297
PCG BRE 009-23 Phase III Randomized Trial of Conventionally Fractionated vs. Hypofractionated COMprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning PROton Therapy (COMPRO): NCT05856773
Gastrointestinal Cancers
NRG GI003 A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma: NCT03186898
NRG GI006 Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer: NCT03801876
Head and Neck Cancers
MSK 16-1416 A Phase II Randomized Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Unilateral Head and Neck Cancer: NCT02923570
ECOG-ACRIN EA3191 A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High-Risk Features: NCT04671667
Pediatric Cancers
Proton and Photon Consortium Registry (PPCR) A Multi Center Registry of Pediatric Patients Treated with Radiation Therapy: NCT01696721
MSK 14-186 Local Control with Reduced-dose Radiotherapy for High-Risk Neuroblastoma: NCT02245997
COG ACNS1723 A Phase II Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (IND# 145355): NCT03919071
COG ARST2031 A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma: NCT04994132
COG ACNS2021 A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor: NCT04684368
PAC PED23-022 N10: Reduced Therapy for High-Risk Neuroblastoma
Prostate Cancer
NYPC 2020-027 Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer: NCT04842890
Recurrent Cancer
NYPC 2019-002 Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors: NCT05313191
Thoracic Cancers
NRG LU008 Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer: NCT05624996
MSK 22-098 Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Patients With Pleural Metastases From Thymic Malignancies: NCT05354570
NYPC 2021-030 Patient Generated Health Data Collection During Chemoradiotherapy for Lung Cancer: A Pilot Study: NCT06342284
Skin Cancers
MSK 22-090 A Phase II, Multicenter, Single-Arm Clinical Trial of Definitive Radiotherapy And CeMiPlimAb-Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: NCT05574101
All Cancer Types
PCG REG001-09 Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy: NCT01255748
Proton Therapy Effectiveness
Clinical data validates proton therapy as an effective cancer treatment that is neither experimental nor investigative. We can share our research validating proton therapy as an effective cancer treatment with your insurance provider.
